The Envision Pharma Group (EPG) is promoting its current Chief Commercial Officer, David Thompson, to the position of Chief Executive Officer, taking over the reins from Brian Hepburn who in turn is being promoted to Executive Co Chair for the group. The two new appointments will take effect at the beginning of the New Year.
Mr Hepburn stated: “I can think of no one better to take over the mantle of the CEO for the Group. David has been with the organization for four years now and truly understands its DNA, which is often the biggest challenge for any incoming CEO. In addition, he brings an energy and ‘can do’ attitude to the table which will ensure we continue to innovate and challenge the norm. This planned transition has been in the making for some time now and I look forward to working with him closely on this new phase of the journey for Envision.”
“EPG advancing its leadership team with two promotions. “
Mr Thompson, stated: “I am honoured and truly excited to be taking on the role of CEO for the Envision Pharma Group. The Group has been immensely successful through its unique business model of combining strategic data centric scientific services with best in class technology solutions, such as the gold standard publication planning tool, Datavision. I look forward to continuing that journey through organic growth with a focus on expanding our medical affairs value proposition via the iEnvision platform. We also plan to grow our footprint through strategic acquisitions for key adjacent services. Undoubtedly we have a unique opportunity to provide market leading solutions, through a combination of world class services and technology enablement, to our client base, which will positively impact the effective and efficient dissemination of NCE data to HCPs, payors, and patients alike.”